Does ELOSULFASE ALFA Cause Infusion site extravasation? 29 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 29 reports of Infusion site extravasation have been filed in association with ELOSULFASE ALFA (VIMIZIM). This represents 0.6% of all adverse event reports for ELOSULFASE ALFA.
29
Reports of Infusion site extravasation with ELOSULFASE ALFA
0.6%
of all ELOSULFASE ALFA reports
0
Deaths
2
Hospitalizations
How Dangerous Is Infusion site extravasation From ELOSULFASE ALFA?
Of the 29 reports, 2 (6.9%) required hospitalization.
Is Infusion site extravasation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELOSULFASE ALFA. However, 29 reports have been filed with the FAERS database.
What Other Side Effects Does ELOSULFASE ALFA Cause?
Pyrexia (682)
Cough (318)
Vomiting (308)
Malaise (282)
Headache (242)
Dyspnoea (216)
Nausea (212)
Pain (205)
Nasopharyngitis (183)
Fatigue (177)
What Other Drugs Cause Infusion site extravasation?
HUMAN IMMUNOGLOBULIN G (822)
INFLIXIMAB (435)
INFLIXIMAB-DYYB (328)
TREPROSTINIL (256)
VEDOLIZUMAB (199)
HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN (185)
REMDESIVIR (144)
FERRIC CARBOXYMALTOSE (118)
RITUXIMAB (82)
NATALIZUMAB (70)
Which ELOSULFASE ALFA Alternatives Have Lower Infusion site extravasation Risk?
ELOSULFASE ALFA vs ELOTUZUMAB
ELOSULFASE ALFA vs ELOXATIN
ELOSULFASE ALFA vs ELRANATAMAB
ELOSULFASE ALFA vs ELRANATAMAB-BCMM
ELOSULFASE ALFA vs ELTROMBOPAG